Regeneus and Kyocera ink lucrative deal to commercialise Progenza in $3.5 billion dollar market
Aug 11, 2020
Aug 11, 2020 |
6 min
Japan is an important market for clinical stage regenerative medicine company, Regeneus Ltd (ASX: RGS), which has just negotiated a license agreement with Kyocera Corporation (Kyocera, TYO:6971) to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan.
Regeneus surges on back of Progenza patent news
Mar 23, 2020
Mar 23, 2020 |
2 min
The US Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for clinical-stage regenerative medicine company Regeneus Ltd's (ASX: RGS) lead stem cell platform technology Progenza.
Knee osteoarthritis treatment delivers Regeneus a A$1.6M milestone payment
Mar 20, 2020
Mar 20, 2020 |
1 min
Regeneus Ltd (ASX: RGS) today received a non-refundable milestone payment of ¥100M (approx. A$1.6M) from Kyocera Corporation (TYO:6971).
Regeneus inks agreement with high profile Japanese life sciences group
Mar 3, 2020
Mar 3, 2020 |
4 min
Clinical stage regenerative medicine company Regeneus Ltd (ASX:RGS) has signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in the life sciences industry.
Can This ASX Junior Surge Through the Pain Barrier?
Mar 2, 2020
Mar 2, 2020 |
14 min
Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.
